+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Wilms Tumor Protein"

TCR-based Therapies Market by Target Indications, Target Antigens, Key Players and Key Geographies, Industry Trends and Global Forecasts, 2021-2030 - Product Thumbnail Image

TCR-based Therapies Market by Target Indications, Target Antigens, Key Players and Key Geographies, Industry Trends and Global Forecasts, 2021-2030

  • Report
  • March 2021
  • 397 Pages
  • Global
From
Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019-2030 - Product Thumbnail Image

Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019-2030

  • Report
  • July 2019
  • 800 Pages
  • Global
From
Global T-Cell Therapy Market - Distribution by Type of Therapy, Target Indications, Target Antigens, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035 - Product Thumbnail Image

Global T-Cell Therapy Market - Distribution by Type of Therapy, Target Indications, Target Antigens, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

  • Report
  • August 2022
  • 1180 Pages
  • Global
From
Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019 - Product Thumbnail Image

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 80 Pages
  • Global
From
Cancer Testis Antigen 1 - Pipeline Review, H2 2019 - Product Thumbnail Image

Cancer Testis Antigen 1 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 76 Pages
  • Global
From
Wilms Tumor Protein Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Wilms Tumor Protein Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • February 2024
  • 86 Pages
  • Global
From
Cells Expressing Wilms Tumor Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Wilms Tumor Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 57 Pages
  • Global
From
Wilms Tumor Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Wilms Tumor Protein Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 45 Pages
  • Global
From
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2018 - Product Thumbnail Image

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2018

  • Drug Pipelines
  • August 2018
  • 74 Pages
  • Global
From
  • 9 Results (Page 1 of 1)
Loading Indicator

The Wilms Tumor Protein (WT1) is a protein that is expressed in Wilms tumors, a type of cancer that affects the kidneys. WT1 is a promising target for the development of oncology drugs, as it is involved in the regulation of cell growth and differentiation. WT1-targeted therapies have the potential to be used in combination with other treatments, such as chemotherapy and radiation, to improve outcomes for patients with Wilms tumors. Several companies are developing WT1-targeted therapies for the treatment of Wilms tumors. These include Novartis, which is developing a WT1-targeted antibody-drug conjugate, and Merck, which is developing a WT1-targeted small molecule. Other companies, such as AstraZeneca and Pfizer, are also researching WT1-targeted therapies. Show Less Read more